贝伐珠单抗治疗铂耐药卵巢癌、输卵管癌、腹膜癌患者的临床研究  

Clinical trial of bevacizumab in the treatment of platinum-resistant ovarian cancer,tubal cancer and peritoneal carcinoma patients

作　　者：宓淑芳[1] 张立梅 李沫 梁彩娟 MI Shu-fang;ZHANG Li-mei;LI Mo;LIANG Cai-juan(Department of Obstetrics and Gynecology,Beihua University Affiliated Hospital,Jilin 132001,Jilin Province,China)

机构地区：[1]北华大学附属医院妇产科,吉林吉林132001

出　　处：《中国临床药理学杂志》2023年第23期3379-3383,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：目的 观察贝伐珠单抗治疗铂耐药卵巢癌、输卵管癌、腹膜癌患者的临床疗效和安全性。方法 纳入接受贝伐珠单抗治疗的卵巢癌、输卵管癌、腹膜癌对铂耐药患者为试验组;另纳入同期我院接受多西他赛化疗的卵巢、输卵管、腹膜癌对铂耐药患者为对照组。试验组给予贝伐珠单抗5 mg·kg^(-1),静脉输注,每2周给药1次,首次静脉输注时间需持续90 min,共化疗4次;对照组给予多西他赛70~75 mg·m^(-2),静脉输注,每3周给药1次,每次1 h,共化疗4次。比较2组患者化疗结束后的临床疗效,比较化疗前及化疗后血清鳞状上皮细胞癌抗原(SCC-Ag)、恶性肿瘤相关物质群(TSGF)、细胞角蛋白19片段(CYFRA21-1)水平、肿瘤标志物变化、免疫指标和药物不良反应发生情况。结果 试验组70例,对照组50例。化疗4次后,试验组和对照组的总有效率分别为47.14%(33例/70例)和30.00%(15例/50例),差异有统计学意义(P<0.05)。化疗后,试验组和对照组的SCC-Ag分别为(3.10±1.05)和(5.50±1.95)mg·L^(-1),TSGF分别为(30.20±9.94)和(56.70±10.45)U·mL^(-1),CYFRA21-1分别为(1.03±0.45)和(2.10±0.99)mg·L^(-1),癌胚抗原(CEA)分别为(66.81±48.74)和(89.18±56.08)ng·mL^(-1),肿瘤标志物(CA199)分别为(110.26±51.36)和(124.13±53.80)U·mL^(-1),胃癌抗原(CA724)分别为(14.70±9.72)和(20.54±18.51)U·mL^(-1),CD3^(+)分别为(72.45±9.45)%和(67.10±10.25)%,CD4^(+)分别为(48.49±9.15)%和(39.56±6.77)%,CD8^(+)分别为(20.18±3.85)%和(24.02±4.45)%,差异均有统计学意义(均P<0.05)。2组的药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论 贝伐珠单抗比多西他赛对铂耐药卵巢癌、输卵管癌、腹膜癌患者的临床疗效更佳。Objective To observe the clinical efficacy and safety of bevacizumab in the treatment of platinum-resistant ovarian cancer,tubal cancer,peritoneal carcinoma cancer.Methods Patients with platinum resistance ovarian cancer,tubal cancer and peritoneal carcinoma cancer treated with bevacizumab were in included into treatment group.Patients with platinum-resistance in ovarian cancer,tubal cancer and peritoneal carcinoma cancer who received docetaxel chemotherapy during the same period were included into control group.The treatment group was given bevacizumab 5 mg·kg^(-1)by intravenous infusion once every 2 weeks,and the first intravenous infusion lasted for90 min,with a total of 4 times of chemotherapy.The control group was given docetaxel 70-75 mg·m^(-2)by intravenous infusion,once every 3 weeks,1 h each time,a total of 4 times of chemotherapy.The clinical efficacy after chemotherapy,the levels of serum squamous cell carcinoma antigen(SCCAg),malignant tumor-related substance group(TSGF),cytokeratin 19 fragment(CYFRA21-1),the changes of tumor markers,immune indexes and the occurrence of adverse drug reactions were compared between the two groups.Results There are 70 cases in treatment group and 50 cases in control group.After four rounds of chemotherapy,the total effective rates of treatment group and control group were 47.14%(33 cases/70 cases)and 30.00%(15 cases/50cases),with statistically significant difference(P<0.05).After chemotherapy,the SCC-Ag levels in treatment group and control group were(3.10±1.05)and(5.50±1.95)mg·L^(-1);TSGF levels were(30.20±9.94)and(56.70±10.45)U·mL^(-1);CYFRA21-1 levels were(1.03±0.45)and(2.10±0.99)mg·L^(-1);carcinoembryonic antigen(CEA)levels were(66.81±48.74)and(89.18±56.08)ng·mL^(-1);the tumor markers CA199 were(110.26±51.36)and(124.13±53.80)U·mL^(-1);the gastric cancer antigen(CA724)were(14.70±9.72)and(20.54±18.51)U·mL^(-1);the CD3^(+)levels were(72.45±9.45)%and(67.10±10.25)%;the CD4^(+)levels were(48.49±9.15)%and(39.56±6.77)%;the CD8^(+)levels were(20.18±3

关 键 词：贝伐珠单抗 多西他赛 卵巢癌 输卵管癌 腹膜癌 

分 类 号：R979.1[医药卫生—药品]